Abstract：
OBJECTIVE: The aim of the observational cohort study is to study and evaluate the efficiency of the drug Adenoprosin in combination with other drugs in comparison with monotherapy.
METHODS: Data from 6,442 patients at 221 medical institutions in 39 cities from November 2020 to December 2022 were analyzed. The drug Adenoprosin in the form of rectal suppositories was prescribed as monotherapy in group I, while patients in group II received Adenoprosin in a combination with other drugs. The efficacy of treatment was assessed using uroflowmetry data, prostate volume, postvoid residual volume and validated scales (NIH-CPSI, IIEF-5, IPSS, QoL).
RESULTS: The diagnosis was validated in 6375 cases, including BPH (n=1498), chronic prostatitis (CP; n=3060), and in combination of both disorders (n=1817). A total of 3580 patients received Adenoprosin as monotherapy, while 2761 received combination therapy. In most cases, a combination therapy was prescribed in case of more severe disease. In patients with BPH, positive changes after treatment were noted in favor of group I according to change in postvoid residual volume (p<0.001) and prostate volume (p<0.001). Combination therapy demonstrated significant positive changes compared with monotherapy when assessing NIH-CPSI scores (p=0.005), IPSS scores (p<0.001) and the mean maximum urine flow rate (Qmax; p<0.001). Qmax increased significantly in both groups (from 14 ml/s to 17 ml/s in group I and from 12 ml/s to 14 ml/s in group II).
CONCLUSIONS: Treatment of BPH, CP and their combination is a complex clinical task. The multiple nature of complaints often dictates the need for simultaneous administration of two or more drugs. Combination therapy involves the use of multiple therapeutic strategies to treat different aspects of BPH and CP. In patients with BPH, a combination therapy has been shown to be more effective than monotherapy with either class of drugs, as it reduces the risk of disease progression, acute urinary retention, and the need for surgery. However, combination therapy should be considered on an individual basis, taking into account symptoms, prostate size and overall health. There is no universal treatment method for BPH suitable for any patient. The treatment strategy should be chosen individually, considering all medical and social factors. All of the above applies to a large extent to the treatment of CP and CP + BPH. According to our results, Adenoprosin demonstrated efficacy both as monotherapy and in combination with other traditional drugs in the treatment of men with lower urinary tract symptoms.
METHODS: Data from 6,442 patients at 221 medical institutions in 39 cities from November 2020 to December 2022 were analyzed. The drug Adenoprosin in the form of rectal suppositories was prescribed as monotherapy in group I, while patients in group II received Adenoprosin in a combination with other drugs. The efficacy of treatment was assessed using uroflowmetry data, prostate volume, postvoid residual volume and validated scales (NIH-CPSI, IIEF-5, IPSS, QoL).
RESULTS: The diagnosis was validated in 6375 cases, including BPH (n=1498), chronic prostatitis (CP; n=3060), and in combination of both disorders (n=1817). A total of 3580 patients received Adenoprosin as monotherapy, while 2761 received combination therapy. In most cases, a combination therapy was prescribed in case of more severe disease. In patients with BPH, positive changes after treatment were noted in favor of group I according to change in postvoid residual volume (p<0.001) and prostate volume (p<0.001). Combination therapy demonstrated significant positive changes compared with monotherapy when assessing NIH-CPSI scores (p=0.005), IPSS scores (p<0.001) and the mean maximum urine flow rate (Qmax; p<0.001). Qmax increased significantly in both groups (from 14 ml/s to 17 ml/s in group I and from 12 ml/s to 14 ml/s in group II).
CONCLUSIONS: Treatment of BPH, CP and their combination is a complex clinical task. The multiple nature of complaints often dictates the need for simultaneous administration of two or more drugs. Combination therapy involves the use of multiple therapeutic strategies to treat different aspects of BPH and CP. In patients with BPH, a combination therapy has been shown to be more effective than monotherapy with either class of drugs, as it reduces the risk of disease progression, acute urinary retention, and the need for surgery. However, combination therapy should be considered on an individual basis, taking into account symptoms, prostate size and overall health. There is no universal treatment method for BPH suitable for any patient. The treatment strategy should be chosen individually, considering all medical and social factors. All of the above applies to a large extent to the treatment of CP and CP + BPH. According to our results, Adenoprosin demonstrated efficacy both as monotherapy and in combination with other traditional drugs in the treatment of men with lower urinary tract symptoms.
摘要：
目的：观察性队列研究的目的是研究和评估药物腺样体与其他药物联合治疗与单药治疗的疗效。
方法：分析了2020年11月至2022年12月39个城市221家医疗机构的6,442例患者的数据。在第I组中，以直肠栓剂形式的药物腺样体被规定为单一疗法，而II组患者接受了腺样体素与其他药物的联合治疗。使用尿流图数据评估治疗的疗效，前列腺体积,后空隙残余体积和验证的量表(NIH-CPSI，IIEF-5,IPSS,QoL）。
结果：6375例患者的诊断得到证实，包括BPH（n=1498），慢性前列腺炎（CP；n=3060），以及两种疾病的组合（n=1817）。共有3580名患者接受了腺样体作为单一疗法，2761接受联合治疗。在大多数情况下,如果疾病更严重，则规定了联合治疗。在BPH患者中，根据后空隙残余体积(p<0.001)和前列腺体积(p<0.001)的变化,治疗后的阳性变化有利于I组.在评估NIH-CPSI评分时，联合治疗与单药治疗相比显示出显著的积极变化（p=0.005），IPSS评分(p<0.001)和平均最大尿流率(Qmax;p<0.001)。两组的Qmax均显着增加（I组从14ml/s增加到17ml/s，II组从12ml/s增加到14ml/s）。
结论：BPH的治疗，CP及其组合是一项复杂的临床任务。投诉的多重性质通常要求需要同时施用两种或更多种药物。联合治疗涉及使用多种治疗策略来治疗BPH和CP的不同方面。在BPH患者中，联合疗法已被证明比任何一类药物的单一疗法更有效，因为它降低了疾病进展的风险，急性尿潴留,以及手术的需要.然而,联合治疗应考虑在个人的基础上，考虑到症状，前列腺大小和整体健康。没有适用于任何患者的BPH的通用治疗方法。治疗策略应单独选择，考虑到所有医疗和社会因素。以上全部在很大程度上适用于CP和CP+BPH的处置。根据我们的结果,在治疗患有下尿路症状的男性中，腺苷酸作为单一疗法和与其他传统药物联合使用均显示出疗效。
方法：分析了2020年11月至2022年12月39个城市221家医疗机构的6,442例患者的数据。在第I组中，以直肠栓剂形式的药物腺样体被规定为单一疗法，而II组患者接受了腺样体素与其他药物的联合治疗。使用尿流图数据评估治疗的疗效，前列腺体积,后空隙残余体积和验证的量表(NIH-CPSI，IIEF-5,IPSS,QoL）。
结果：6375例患者的诊断得到证实，包括BPH（n=1498），慢性前列腺炎（CP；n=3060），以及两种疾病的组合（n=1817）。共有3580名患者接受了腺样体作为单一疗法，2761接受联合治疗。在大多数情况下,如果疾病更严重，则规定了联合治疗。在BPH患者中，根据后空隙残余体积(p<0.001)和前列腺体积(p<0.001)的变化,治疗后的阳性变化有利于I组.在评估NIH-CPSI评分时，联合治疗与单药治疗相比显示出显著的积极变化（p=0.005），IPSS评分(p<0.001)和平均最大尿流率(Qmax;p<0.001)。两组的Qmax均显着增加（I组从14ml/s增加到17ml/s，II组从12ml/s增加到14ml/s）。
结论：BPH的治疗，CP及其组合是一项复杂的临床任务。投诉的多重性质通常要求需要同时施用两种或更多种药物。联合治疗涉及使用多种治疗策略来治疗BPH和CP的不同方面。在BPH患者中，联合疗法已被证明比任何一类药物的单一疗法更有效，因为它降低了疾病进展的风险，急性尿潴留,以及手术的需要.然而,联合治疗应考虑在个人的基础上，考虑到症状，前列腺大小和整体健康。没有适用于任何患者的BPH的通用治疗方法。治疗策略应单独选择，考虑到所有医疗和社会因素。以上全部在很大程度上适用于CP和CP+BPH的处置。根据我们的结果,在治疗患有下尿路症状的男性中，腺苷酸作为单一疗法和与其他传统药物联合使用均显示出疗效。
